Rabkin C S, Yellin F
Epidemiology Branch, National Cancer Institute, Bethesda, Md 20892.
J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6. doi: 10.1093/jnci/86.22.1711.
Human immunodeficiency virus type 1 (HIV-1) infection is known to increase the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma. Parallels with other causes of immunodeficiency suggest a possible effect of HIV-1 on additional cancers.
This study was designed to determine the types and rates of cancers occurring in excess in the presence of HIV-1 infection.
We examined cancer incidence in a population-based open cohort with a high prevalence of HIV-1 infection. The study population was never-married men aged 25-54 years who resided in San Francisco, Calif., of whom an estimated 20,000 (24%) were HIV-1 seropositive as of late 1984. Cancer registration data covering 1,390,000 person-years of observation of these men from 1973 through 1990 were obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Standardized incidence rates and ratios of observed to expected cases (based on rates in the pre-acquired immunodeficiency syndrome [pre-AIDS] period [i.e., 1973-1979]) were calculated for cancers classified by site and by cell type.
The incidence of Kaposi's sarcoma in never-married men plateaued in 1988-1990 at 0.5% per year. The incidence of non-Hodgkin's lymphoma increased 20-fold between 1973-1979 and 1988-1990; increases were most pronounced in tumors of higher grade histology and extranodal (especially central nervous system) primary sites. The incidence of Burkitt's and Burkitt-like tumors peaked in 1985-1987, whereas that of large cell diffuse and immunoblastic lymphomas increased throughout the study period. The incidence of Hodgkin's disease was 2.0 (95% confidence interval [CI] = 1.3-3.0) times expected in 1988-1990. The incidence of anal cancer was 9.9 (95% CI = 4.5-18.7) times expected in 1973-1979 and 10.1 (95% CI = 5.0-18.0) times expected in 1988-1990. Ratios of observed to expected cancers of most other sites were 2.0 or less; the ratio of leiomyosarcomas (at any site) was 2.5 (95% CI = 0.5-7.4).
As the HIV-1 epidemic has progressed, the increases in AIDS-related Kaposi's sarcoma, Burkitt's tumor, and other non-Hodgkin's lymphoma have followed different patterns. The effect of HIV-1 on other cancers has been nondetectable. In particular, HIV-1 is not related to the increased risk of anal cancer in homosexual men, which antedated the AIDS epidemic.
These data suggest that the etiologic mechanisms of HIV-1-related malignancy differ for specific cancers and do not globally increase cancer risk. Control of HIV-1-related cancer remains an unsolved challenge in the management of HIV-1 infection.
已知人类免疫缺陷病毒1型(HIV-1)感染会增加卡波西肉瘤和非霍奇金淋巴瘤的发病率。与其他免疫缺陷病因的相似之处表明,HIV-1可能对其他癌症产生影响。
本研究旨在确定在存在HIV-1感染的情况下额外发生的癌症类型和发生率。
我们在一个HIV-1感染率很高的基于人群的开放队列中研究癌症发病率。研究人群为居住在加利福尼亚州旧金山的25至54岁未婚男性,截至1984年末,估计其中20,000人(24%)为HIV-1血清阳性。从美国国立癌症研究所的监测、流行病学和最终结果(SEER)项目中获得了1973年至1990年对这些男性1,390,000人年观察期的癌症登记数据。按部位和细胞类型分类的癌症计算了标准化发病率以及观察病例与预期病例的比率(基于获得性免疫缺陷综合征前期[即1973 - 1979年]的数据)。
未婚男性中卡波西肉瘤的发病率在1988 - 1990年稳定在每年0.5%。非霍奇金淋巴瘤的发病率在1973 - 1979年至1988 - 1990年间增加了20倍;在组织学分级较高和结外(尤其是中枢神经系统)原发部位的肿瘤中增加最为明显。伯基特淋巴瘤和伯基特样肿瘤的发病率在1985 - 1987年达到峰值,而大细胞弥漫性和免疫母细胞性淋巴瘤的发病率在整个研究期间都有所增加。霍奇金病的发病率在1988 - 1990年为预期的2.0倍(95%置信区间[CI]=1.3 - 3.0)。肛门癌的发病率在1973 - 1979年为预期的9.9倍(95% CI = 4.5 - 18.7),在1988 - 1990年为预期的10.1倍(95% CI = 5.0 - 18.0)。大多数其他部位观察到的癌症与预期癌症的比率为2.0或更低;平滑肌肉瘤(任何部位)的比率为2.5(95% CI = 0.5 - 7.4)。
随着HIV-1流行的发展,与艾滋病相关的卡波西肉瘤、伯基特淋巴瘤和其他非霍奇金淋巴瘤的增加呈现出不同的模式。未检测到HIV-1对其他癌症的影响。特别是,HIV-1与同性恋男性肛门癌风险增加无关,肛门癌风险增加早于艾滋病流行。
这些数据表明,HIV-1相关恶性肿瘤的病因机制因特定癌症而异,并非全球范围内增加癌症风险。在HIV-1感染的管理中,控制与HIV-1相关的癌症仍然是一个未解决的挑战。